Cargando…
Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models
Bone abnormalities affect all individuals with Down syndrome (DS) and are linked to abnormal expression of DYRK1A, a gene found in three copies in people with DS and Ts65Dn DS model mice. Previous work in Ts65Dn male mice demonstrated that both genetic normalization of Dyrk1a and treatment with ~9 m...
Autores principales: | Jamal, Raza, LaCombe, Jonathan, Patel, Roshni, Blackwell, Matthew, Thomas, Jared R., Sloan, Kourtney, Wallace, Joseph M., Roper, Randall J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865638/ https://www.ncbi.nlm.nih.gov/pubmed/35196359 http://dx.doi.org/10.1371/journal.pone.0264254 |
Ejemplares similares
-
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice
por: Goodlett, Charles R., et al.
Publicado: (2020) -
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016) -
Interaction of sexual dimorphism and gene dosage imbalance in skeletal deficits associated with Down syndrome
por: Thomas, Jared R., et al.
Publicado: (2020) -
Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts
por: Thomas, Jared R., et al.
Publicado: (2021) -
Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives
por: Zhong, Ying, et al.
Publicado: (2012)